| 产品描述: | M1069 is a selective and orall active, dual A2A/A2B adenosine receptor antagonist with a selectivity of >100 fold against the A1 and A3 receptors. M1069 counteracts immune-suppressive mechanisms of adenosine, and exhibits anti-tumor activity. |
| 靶点: |
A2AR,A2BR |
| 体外研究: |
Metabolically stressful conditions, including inflammation and cancer, induces extracellular concentrations of adenosine increase.
M1069 dose-dependently suppresses 5’-N-ethylcarboxamide adenosine (stable analog of adenosine)-stimulated cyclic adenosine monophosphate (cAMP) and phosphorylated cAMP- response element binding protein (pCREB) induction, inhibits interleukin (IL)-2 production.
M1069 suppresses vascular endothelial growth factor (VEGF) production from human macrophages in adenosine-rich settings.
M1069 inhibits protumorigenic cytokine secretion, such as CXCL1, CXCL5 and granulocyte-colony stimulating factor, and reduces IL-12 secretion from adenosine-differentiated dendritic cells.
M1069 enhances T-cells activation in adenosine-differentiated dendritic cells. |
| 体内研究: |
M1069 inhibits breast tumor (CD73hi/adenosine-rich 4T1 syngeneic) growth in vivo in mice and enhances chemotherapeutic agents efficacy. |
| 保存条件: |
2-8°C, 干燥 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.83 ml |
9.148 ml |
18.295 ml |
| 5 mM |
0.366 ml |
1.83 ml |
3.659 ml |
| 10 mM |
0.183 ml |
0.915 ml |
1.83 ml |
| 50 mM |
0.037 ml |
0.183 ml |
0.366 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |